Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

 

Presenting CataloniaBio & HealthTech Blog Post

A new era for the CataloniaBio association of companies and the HealthTech Cluster. Members of the two organisations unanimously passed the motion to merge under the brand CataloniaBio & HealthTech at their respective extraordinary general meetings held in Barcelona yesterday.The headquarters will be located at the Barcelona Science Park. It will promote the convergence of biopharma, MedTech and digital health companies to boost competitiveness and address unmet medical needs 

 

Cebiotex launches a €650,000 crowdfunding campaign to ensure that its oncological treatment reaches paediatrics Blog Post

Cebiotex—with headquarters in the Barcelona Science Park (PCB)—has launched an equity crowdfunding campaign of €650,000 through Capital Cell to ensure that its first drug, CEB-01, used in the local post-surgical treatment of soft tissue sarcomas, also reaches paediatric oncology. CEB-01 is the first therapeutic application of its innovative technology, which are based on nanofibres, for local drug delivery. In the future, however, the company aims to develop new applications for pancreatic and liver cancer, as well as glioblastoma.Since it was formed in 2012, Cebiotex has raised over €2 million from public and private funds. The success of the previous equity crowdfunding campaigns and the participation of impactful social investors has allowed Cebiotex to maintain a paediatric focus as one of the company’s strategic objectives.

 

Closing in on advanced prostate cancer Blog Post

A team headed by Xavier Salvatella, ICREA researcher from the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park, has discovered a new avenue through which to attack prostrate cancer cells that have developed drug-resistance. Published in the journal Structure, part of the Cell group, the study has involved Angel R. Nebreda’s lab and the Experimental Bioinformatics Lab, both at IRB Barcelona, and also the University of Barcelona.  

 

Cells sense their environment to explore it Blog Post

The way cells find their way around is by ‘groping’ rather than seeing their surroundings: this is the main conclusion of a study published in Nature last week involving several IBEC groups and their collaborators. The study was led by Pere Roca-Cusachs, lecturer from the Department of Biomedicine and main researcher at the Institute for Bioengineering of Catalonia (IBEC) at the Barcelona Science Park (PCB).

 

A genetic mutation in the evolution of animals explains the origin of some human organs Blog Post

A neutral genetic mutation –a fluke in the evolutionary process with no apparent biological purpose– that appeared over 700 million years ago in biological evolution could help explain the origin of complex organs and structures in human beings and other vertebrates, according to an article published in Nature Communications by a team led by Professor Jordi García-Fernàndez, from the Faculty of Biology of the University of Barcelona (UB) and the Institute of Biomedicine of the UB (IBUB) at the Barcelona Science Park (PCB), Manuel Irimia (CRG) and Maria Ina Arnone (Anton Dohrn Zoological Station, Italy).

 

The PCB receives the secondary award for best practice in science and technology parks of APTE Blog Post

Ignasi Belda, CEO of the Barcelona Science Park (PCB), has received this morning the secondary prize of the ‘Award for best practice in science and technology parks of Apte’ in the category of parks with an age of more than 10 years. The award ceremony has been delivered within the framework of the XV International Conference of the Association of Science and Technology Parks of Spain (APTE), which is being held today at the Gipuzkoa Science and Technology Park under the name “Beyond 2020: disruptive technologies“.

 

Genesis Biomed presents its new Genesis Ventures fund Blog Post

Today Genesis Biomed has presented at the Barcelona Science Park a new investment fund, Genesis Ventures, made up of various family offices that are looking to invest in research and business projects in the very early stages in the field of biomedicine. With this initiative, the company based at PCB, wants to help entrepreneurs put together the capital they need for their research in order to later attract series-A corporate funds or venture capital.